Gilead Sciences, Inc. (NASDAQ:GILD) has been given an average recommendation of “Buy” by the thirty-three ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation, nineteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $85.19.
Several equities analysts recently weighed in on the stock. Leerink Swann lifted their target price on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, October 19th. BMO Capital Markets restated an “outperform” rating and set a $82.00 target price (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Mizuho lifted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday. Cowen and Company reiterated an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 2nd.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $83.11, for a total value of $6,094,705.63. Following the transaction, the insider now owns 2,996,766 shares in the company, valued at approximately $249,061,222.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last quarter, insiders sold 446,819 shares of company stock worth $36,269,486. Company insiders own 1.30% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Welch Investments LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth $108,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the last quarter. Penserra Capital Management LLC increased its stake in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. American Beacon Advisors Inc. bought a new stake in shares of Gilead Sciences during the 1st quarter worth $143,000. Finally, Horan Capital Advisors LLC. bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $144,000. Institutional investors own 74.38% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Given Consensus Recommendation of “Buy” by Brokerages” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/11/12/gilead-sciences-inc-gild-given-consensus-recommendation-of-buy-by-brokerages.html.
Gilead Sciences (NASDAQ:GILD) traded up $0.75 during trading hours on Friday, hitting $73.77. 7,698,200 shares of the company traded hands, compared to its average volume of 9,244,684. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 4.74. The firm has a market cap of $96,363.46, a price-to-earnings ratio of 7.70, a price-to-earnings-growth ratio of -1.24 and a beta of 1.13. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.75 EPS. equities research analysts forecast that Gilead Sciences will post 8.53 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.82%. Gilead Sciences’s dividend payout ratio is presently 23.69%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.